Tumour Models London Conference 2nd to 4th December 2014 London, United Kingdom

Off the back of what is set to be a fantastic couple of days in Boston for the Tumor Model community, we are pleased to show you what's in store for the 4th Tumour Models Summit, London!
The number one aim of this year's Tumour Model London meeting is to improve the predictability and translatability of preclinical oncology research
This is the must attend meeting for preclinical oncologists, translational scientists and tumour model developers who are constantly striving to improve the predictive ability of basic oncology research and the translational success of their candidates.
With an in-depth focus on cutting edge in vivo and in vitro modelling best practice, you will discover how the movement towards more physiologically relevant models will better mimic the tumour environment, better represent the patient population and help you prioritise the best drug candidates.
Gain access to exclusive unpublished case study data, excellent networking sessions with senior level executives and industry-defining information on effective preclinical strategies that will improve the data interpretation from your tumour model studies and reduce failure rates of oncology clinical trials.
Sound interesting?
Here’s a quick snapshot of what you’ll get from attending Tumour Models London:

1. Discover the latest developments in clinically relevant tumour models in preclinical trials and enhance your successful drug development.
   
2. Learn about the most innovative immune-competent in vitro and in vivo models being used in the development cancer-immunotherapies. 
   
3. Harness PDX models to improve the representation of the patient population in preclinical clinical trials and enhance translational decision making.
   
4. Discover the emergence of 3D  modelling in drug candidate development to specifically target the tumour microenvironment.
   
5. Explore the advanced pharmaco-imaging technology being used to monitor the pharmacokinetics in tumour models and improve drug efficacy. 
   
6. Harness in vitro modelling to investigate drug resistance and efficacy.
   
7. Explore how tumour modelling can enhance the development of combination therapies.
   
8. Discover the technological advancements in the field of preclinical tumour modelling and improve your preclinical predictions.
   
9. Learn how introducing Next Generation sequencing into preclinical practise can improve the development of personalised medicines.
   
10. Understand the importance of enhancing translational collaborations to improve drug discovery, efficacy testing and overall translational success.
    

Website: http://tumour-models.com/
Contact person: Charlotte Parnaby